No annual revenue total was found in Aktis Oncology, Inc.'s SEC filings.
Aktis Oncology, Inc. (AKTS) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $517.3 million in cash and investments and $400,000 in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$516.92M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2035832
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 16, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
All 62 Aktis Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.